Page 2 - Lead Program News Today

Today, the New York City Coalition to End Lead Poisoning (NYCCELP), a coalition of advocates, doctors, lawyers, and the Lead Roundtable, which is convened by the coalition, released the “2022 Lead Agenda: A Roadmap to Eliminating Lead Poisoning in New York City.” Our city’s children continue to needlessly suffer permanent neurological damage from exposure to lead in old paint, dust, and drinking water in their homes.

Investegate announcements from PureTech Health PLC, PRTCs Vedanta Publishes VE303 Data

The Milwaukee County District Attorney’s Office has reviewed an investigation regarding the City of Milwaukee Health Department Childhood Lead Poisoning Prevention Program. Officials say there is insufficient evidence to prove a crime was committed.

/PRNewswire/ -- The National LGBT Chamber of Commerce (NGLCC), the business voice of the LGBT community, is proud to announce an exciting new program for LGBT...

/PRNewswire/ -- The National LGBT Chamber of Commerce (NGLCC), the business voice of the LGBT community, is proud to announce an exciting new program for LGBT...

Absa 2022 Graduate Talent Program for young Kenyan graduates Application Deadline: 15th December 2021

The latest news on the science of Biotechnology, from the best sources of Biotechnology news. Get the latest Biotechnology news now.

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

A monarch butterfly on a sunflower When Laura Hill bought a house in Burlingtons Old North End, she was warned about the lead. Until it was banned in the U.S. in 1978, lead paint was used in many homes. Lead remediation had been done inside the home, but Hill said there were likely still high levels of lead on and around the outside walls and in the soil. "It struck me, because it was my neighborhood and I saw people growing food in their yards nex...

Share this article Share this article LA JOLLA, Calif., March 15, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress.        "In 2020, we made significant advances across our AOC pipeline and platform. Our work ...